Citius Pharmaceuticals, Inc. (CTXR) vs Pasithea Therapeutics Corp. (KTTA)
A side-by-side comparison of Citius Pharmaceuticals, Inc. and Pasithea Therapeutics Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTXR
Citius Pharmaceuticals, Inc.
$0.50HealthcareDelayed quote: Oct 6, 2026, 12:38 PM EDT
KTTA
Pasithea Therapeutics Corp.
$0.45HealthcareDelayed quote: Oct 6, 2026, 12:37 PM EDT
Total return — CTXR vs KTTA
growth of $100 · dividends reinvested · last 5yCTXR -99.0% (-60.2%/yr)KTTA -99.4% (-63.6%/yr)CTXR compounded faster over this window
CTXR KTTA
CTXR vs KTTA: by the numbers
- •KTTA is the larger company ($15M vs $14M market cap).
- •Both run net losses; KTTA's is the smaller (0.00% vs -651.27% net margin).
Metrics side by side
Valuation
| Metric | CTXR | KTTA |
|---|---|---|
| P/S ratio | 1.94 | N/A |
| P/B ratio | 0.21 | 0.30 |
Profitability
| Metric | CTXR | KTTA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | -651.27% | 0.00% |
| ROE | -69.47% | -42.72% |
| ROIC | -67.62% | -48.04% |
Growth (annualized)
| Metric | CTXR | KTTA |
|---|---|---|
| Total return CAGR (5Y) | -60.04% | -61.48% |
Frequently asked
- How have CTXR and KTTA total returns compared?
- Over the past 5 years, CTXR delivered -60.04% and KTTA delivered -61.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.